IL1B and chronic kidney disease: Decreasing the gut production (or increasing the removal) of circulating DAMPs in uremia and/or anti-inflammatory treatments that target the NLRP3 to IL-1 to IL-6 pathway of innate immunity may offer a new paradigm to treat CKD-related PEW and CVD.